Related Experiment Video
Updated: May 23, 2026
Establishing a Silicosis Rat Model via Exposure of Whole-Body to Respirable Silica
Published on: October 28, 2022
[Observe effect the treatment of HanFangJiaSu on pneumoconiosis]
Ding-zi Zhou1, Li-jun Peng, Qi-shang Zhu
1West China Clincal Medical School & West China the Fourth Hospital, Sichuan University, Chengdu 610041, China.
Objective:
To observe the curative effect of HanFangJiaSu on pneumoconiosis.
Method:
71 patients with silicosis were divided into trial group and control group at random. The treating group (36 patients) was treated 90 days with HanFangJiaSu and The control group (35 patients) was treated 90 days with XiFeiNing. The silicosis with cough,chest complaint, dyspnoea and immune modulation were observed before treating and after treating. The effect was compared between the two groups.
Result:
To compared with the group before treatment and the control group, the symptoms score of cough, chest complaint and dyspnoea in treated group was significantly decreased after treatment(P<0.05). The rate was decreased by 69.35% in treated group and 50.00% in controls, which showed the treatment in both groups was effective. The rate in treated group was significantly decreased more than in controls(P<0.05). There were 13 cases with respiratory tract infection and 2 cases with lung infection in treated group of which percentage were 36.11% and 5.55%, while 22 cases and 4 cases in control group of which percentage were 57.14% and 28.57%. There was a significant difference between the two groups (P<0.05). To compared with the group before treatment, the quantity of CD(4) in blood was obviously increased, while CD(8) was obviously decreased, which showed a significant increase of CD(4)/ CD(8), (P<0.05). To compared with control group, the quantity of CD(4) in treated group was obviously increased, while CD8 was obviously decreased, which also showed a significant increase of CD(4)/CD(8) (P<0.05). There was no significant difference with the concentration of immune globulin (IgG, IgA, IgM) between the groups before and after treatment.
